Refractory Gout

New Biological Agents for the Management of Refractory Gout

Print This Post Print This Post

CME Information


expired

Learning Objectives

After participating in this educational activity, participants should be better able to:

  1. Monitor serum uric acid in order to set and achieve the target levels using all modes of therapies
  2. Anticipate and manage adverse events associated with aggressive urate-lowering therapy

 

Introduction

Primary care providers are increasingly called upon to manage gout, a once less common disease that is becoming more prevalent and difficult to treat as our society rapidly ages. Gout is also on the rise and increasingly severe due to the increasing prevalence of obesity as well as animal fats and high fructose corn syrup in the Western diet. This presents a significant clinical challenge considering the traditionally very limited armamentarium of therapies available to clinicians practicing in the primary care setting. Fortunately, this is changing, as new therapeutic options for gout – including refractory gout – have emerged in the past few years. There has also been a rapid recent increase in our understanding of how to use traditional therapies for the treatment of gout in the primary care setting. This educational program will provide up-to-date information on managing gout, with particular emphasis on the use of biologics for refractory gout.

 

Published on September 11, 2012

This activity has expired and is no longer available for CME; however, we hope you still enjoy the education.